Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18889881 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL18611603 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL22932137 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL246192 | 0.98 | TSHR (0.48) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL21800787 | 0.95 | TSHR (0.46) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL22932140 | 0.94 | MEN1 (0.45) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL18611911 | 0.94 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL9541679 | 0.88 | KDM4E (0.45) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL9540608 | 0.88 | KDM4E (0.45) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL14198320 | 0.88 | KDM4E (0.45) | MEN1KMT2AALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180257022-A1 | ABSORPTION AGENT AND A METHOD FOR SELECTIVELY REMOVING HYDROGEN SULPHIDE | BASF SE (DE) | 2018-09-13 | — | — | US | claimed |
| EP-3356014-A1 | ABSORPTION AGENT AND A METHOD FOR SELECTIVELY REMOVING HYDROGEN SULPHIDE | BASF SE (DE) | 2018-08-08 | — | — | EP | claimed |
| US-20140255250-A1 | INHIBITION OF CORROSION IN BOILER SYSTEMS WITH ETHERAMINES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-09-11 | — | — | US | claimed |
| US-8771594-B2 | Inhibition of corrosion in boiler systems with etheramines | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-07-08 | — | — | US | claimed |
| WO-2013173423-A1 | AMINE GAS TREATMENT SOLUTIONS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-11-21 | — | — | WO | claimed |
| US-20130309129-A1 | INHIBITION OF CORROSION IN BOILER SYSTEMS WITH ETHERAMINES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-11-21 | — | — | US | claimed |
| US-20130310623-A1 | AMINE GAS TREATMENT SOLUTIONS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-11-21 | — | — | US | claimed |
| US-12138583-B2 | Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring | BASF SE (DE) | 2024-11-12 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| EP-3927450-B1 | PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM WITH A LIQUID ABSORBENT COMPRISING A PIPERAZINE RING | BASF SE (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2013173423-A1 | AMINE GAS TREATMENT SOLUTIONS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310623-A1 | AMINE GAS TREATMENT SOLUTIONS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130240047-A1 | LOW TEMPERATURE TRANSPORT AND STORAGE OF AMINE GAS TREATMENT SOLUTIONS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130142717-A1 | OFFSHORE GAS SEPARATION PROCESS | SISKIN MICHAEL (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013082242-A1 | OFFSHORE GAS SEPARATION PROCESS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | MEN1 1809/4885KMT2A 588/4885TSHR 4784/4885 |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | MEN1 1285/4885KMT2A 1310/4885TSHR 3515/4885 |
| US-20130310623-A1 | AMINE GAS TREATMENT SOLUTIONS | GPX4, OAT, HNMT | MEN1 3493/4885KMT2A 2802/4885TSHR 3422/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | MEN1 1550/4885KMT2A 2363/4885TSHR 1595/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | MEN1 1561/4885KMT2A 1849/4885TSHR 3397/4885 |
| US-12138583-B2 | Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring | AVPR2, HRH2, SLC43A1 | MEN1 2204/4885KMT2A 3480/4885TSHR 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.